Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial
Primary result · VGDRResult — go to the resultDifference 2.0% 95% CI −3.1 to 7.1Authors' conclusion
Among patients who underwent CABG, evolocumab did not reduce SVG disease at 24 months following the index surgery despite substantial LDL-C lowering.
Study context
- Population
- Adults after coronary artery bypass graft (CABG) with ≥2 saphenous vein graft (SVGs) on moderate- or high-intensity statin therapy554 with primary outcome data
- Participants
- 782 adults
- Comparison
- Evolocumab vs placebo
- Evolocumabn = 389
- Placebon = 393reference
- Primary endpoint
- Vein graft disease rate (VGDR; proportion of SVGs with ≥50% occlusion on coronary CT angiography or clinically indicated invasive angiography)
- Follow-up
- 24 months
Methodological detailsmulticentre, double-blind, placebo-controlled, 23 sites in Canada, the USA, Australia, and Hungary
- Multicentre
- Double-blind
- Placebo-controlled
- 23 sites in Canada, the USA, Australia, and Hungary
Primary result
VGDR
Difference
2.0%
95% CI −3.1 to 7.1
P = 0.44
Events by treatment group
Evolocumab vs Placebo
difference 2.0% (95% CI −3.1 to 7.1); P = 0.44
As reported in the abstract
Further findings
| Outcome | Evolocumab | Placebo | Mean placebo-adjusted reduction |
|---|---|---|---|
| LDL-C change · 24 months | −52.4% | −4.0% | 48.4% |
Safety
Adverse events
- Well tolerated, similar adverse event profiles between groups
Original publication
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial. Lancet. Published 1 September 2025. doi:10.
Summarised from the published abstract; every number is checked against it